A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy of Node Positive HER2 Negative Breast Cancer: The ABC Trial

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Node Positive Her2 Negative Breast Cancer
  • Age: Between 19 - 69 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Diagnosis of node positive, HER2 negative, anatomic stage II or III breast carcinoma within one year of diagnosis and free of recurrence. 2. Any ER/PgR status allowed 3. Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined the treating physician, is allowed.

You may not be eligible for this study if the following are true:

  • 1. Known allergy to aspirin 2.Prior malignancy of any type within the past 5 years other than breast cancer, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. 3. Chronic (duration greater than 30 days) daily use of oral steroids


If you are registered as a volunteer, please login to the dashboard to send referrals.